Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Matthew S Davids

Showing results (41-50 of 224) with videos related to

Pageof 23
Sort By:
American Journal of Hematology|August 20, 2010
Serum free light chain analysisMatthew S Davids, Mandakolathur R Murali, David J Kuter
Cancer Journal (Sudbury, Mass.)|February 4, 2016
Inhibition of the Bruton Tyrosine Kinase Pathway in B-Cell Lymphoproliferative DisordersJorge J Castillo, Steven P Treon, Matthew S Davids
The New England Journal of Medicine|June 2, 2016
New Agents to Treat Chronic Lymphocytic LeukemiaAndrew W Roberts, Matthew S Davids, John F Seymour
Blood|January 24, 2018
Tyrosine kinase inhibitors and immune checkpoint blockade in allogeneic hematopoietic cell transplantationRobert J Soiffer, Matthew S Davids, Yi-Bin Chen
British Journal of Haematology|May 17, 2017
A complex case of ibrutinib treatment for a CLL patient on haemodialysisAndrew Aw, Jeffrey M Hellman, Ann Birner, et al.
Leukemia & Lymphoma|May 6, 2021
Matching-adjusted indirect comparisons of safety and efficacy of acalabrutinib versus other targeted therapies in patients with treatment-naïve chronic lymphocytic leukemiaMatthew S Davids, Claire Telford, Sarang Abhyankar, et al.
The Lancet. Oncology|July 28, 2022
PI3K inhibitors in haematological malignanciesJennifer R Brown, Alexey V Danilov, Ann S LaCasce, et al.
Lancet (London, England)|March 31, 2020
Small molecules, big impact: 20 years of targeted therapy in oncologyPhilippe L Bedard, David M Hyman, Matthew S Davids, et al.
Health Physics|May 7, 2010
Medical management of radiation victims in the United StatesMatthew S Davids, Cullen Case, Dennis L Confer, et al.
Blood Advances|April 14, 2020
Pneumocystis jirovecii pneumonia and institutional prophylaxis practices in CLL patients treated with BTK inhibitorsChristine E Ryan, Matthew P Cheng, Nicolas C Issa, et al.
Pageof 23

Showing results (41-50 of 224) with videos related to

Sort By:
Pageof 23
American Journal of Hematology|August 20, 2010
Serum free light chain analysisMatthew S Davids, Mandakolathur R Murali, David J Kuter
Cancer Journal (Sudbury, Mass.)|February 4, 2016
Inhibition of the Bruton Tyrosine Kinase Pathway in B-Cell Lymphoproliferative DisordersJorge J Castillo, Steven P Treon, Matthew S Davids
The New England Journal of Medicine|June 2, 2016
New Agents to Treat Chronic Lymphocytic LeukemiaAndrew W Roberts, Matthew S Davids, John F Seymour
Blood|January 24, 2018
Tyrosine kinase inhibitors and immune checkpoint blockade in allogeneic hematopoietic cell transplantationRobert J Soiffer, Matthew S Davids, Yi-Bin Chen
British Journal of Haematology|May 17, 2017
A complex case of ibrutinib treatment for a CLL patient on haemodialysisAndrew Aw, Jeffrey M Hellman, Ann Birner, et al.
Leukemia & Lymphoma|May 6, 2021
Matching-adjusted indirect comparisons of safety and efficacy of acalabrutinib versus other targeted therapies in patients with treatment-naïve chronic lymphocytic leukemiaMatthew S Davids, Claire Telford, Sarang Abhyankar, et al.
The Lancet. Oncology|July 28, 2022
PI3K inhibitors in haematological malignanciesJennifer R Brown, Alexey V Danilov, Ann S LaCasce, et al.
Lancet (London, England)|March 31, 2020
Small molecules, big impact: 20 years of targeted therapy in oncologyPhilippe L Bedard, David M Hyman, Matthew S Davids, et al.
Health Physics|May 7, 2010
Medical management of radiation victims in the United StatesMatthew S Davids, Cullen Case, Dennis L Confer, et al.
Blood Advances|April 14, 2020
Pneumocystis jirovecii pneumonia and institutional prophylaxis practices in CLL patients treated with BTK inhibitorsChristine E Ryan, Matthew P Cheng, Nicolas C Issa, et al.
Pageof 23